Rapport (RAPP) Q2 Net Loss Widens 47%
Rapport Therapeutics (NASDAQ:RAPP), a neuroscience-focused biotechnology company, reported its second-quarter 2025 results on August 7, 2025. Net loss was $26.7 million, compared to $18.1 million in the prior year period, primarily due to higher clinical development expenses and public company operating costs. Research and development expense was $22.7 million, reflecting pipeline advancement. The company has no revenue, as its programs remain in clinical stages. Earnings per share were $(0.75), less negative than the consensus estimate of $(0.81). Management confirmed that a key Phase 2a epilepsy trial is fully enrolled and on track for results in September 2025. The period’s results align with expectations for a biotech company pushing clinical progress, but the growing net loss and increased cash burn will be important to watch as key milestones approach.
Source: Analyst estimates for the quarter provided by FactSet.
Rapport Therapeutics develops targeted therapies for central nervous system (CNS) disorders. Its lead program, RAP-219, is designed to modulate specific brain receptors with the goal of reducing seizures, treating mood disorders, and addressing neuropathic pain. The company relies on clinical trial progress as its main driver, with no products yet on the market. Current business priorities focus on advancing RAP-219 through clinical studies in focal epilepsy and bipolar disorder.
Source Fool.com
